Skip to main content
Clinical Trials/EUCTR2016-003273-18-FR
EUCTR2016-003273-18-FRActive, not recruitingPhase 1

Effects of intranasal administrations of oxytocin on beahvioural troubles, hyperphagia and social skills in children with Prader-Willi syndrome aged from 3 to 12 years. - OXYJEUNE

niversity Hospital of Toulouse0 sites40 target enrollmentStarted: August 22, 2016Last updated:
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • patient with a complete genetic diagnosis of PWS
  • patient aged from 3 to 12 years
  • patient treated by growth hormone for at least 1 year
  • patient naïve for OXT for at least 5 years
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 40
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • patient who do not accept intranasal administrations (major behavioural trouble)
  • patient with hepatic insufficiency : serum transaminases higher than 3 times normal values for age
  • patient with renal insufficiency : serum creatinine higher than 3 times normal values for age
  • patient with an antecedent of abnormal electrocardiogram
  • patient with arterial hypertension or hypotension
  • patient with type 1 or 2 diabetes

Investigators

Sponsor
niversity Hospital of Toulouse

Similar Trials